CM
ADMA icon

Caption Management’s ADMA Biologics ADMA Stock Holding History

Caption Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.6M Sell
550,000
-975,300
-64% -$8.89M 0.02% 611
2026
Q1 		$13.7M Buy
1,525,300
+1,212,800
+388% +$19.1M 0.08% 268
2025
Q4 		$5.7M Buy
312,500
+15,000
+5% +$253K 0.04% 481
2025
Q3 		$4.36M Sell
297,500
-50,100
-14% -$859K 0.03% 542
2025
Q2 		$6.33M Buy
347,600
+700
+0.2% +$14.3K 0.07% 334
2025
Q1 		$6.88M Buy
+346,900
New +$6M 0.07% 289

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Caption Management's ADMA Position: Q2 2026 in Review

Caption Management reduced its ADMA Biologics (ADMA) stake by 29% in Q2 2026, selling an estimated $1.73M and leaving 470,000 shares worth $3.93M. The position accounts for 0.02% of the portfolio, ranked #653.

Caption Management first reported a position in ADMA in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.95M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Caption Management held 470,000 shares of ADMA Biologics worth $3.93M as of Q2 2026.
  • Caption Management sold 190,000 ADMA Biologics shares in Q2 2026, an estimated $1.73M.
  • ADMA Biologics made up 0.02% of Caption Management's portfolio in Q2 2026, its #653 holding.
  • Caption Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 4 quarters since.
  • Caption Management's ADMA Biologics position peaked at $5.95M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.